Insights about U.S. Stocks that landed in the Red-Zone during Wednesday’s trade, are depicted underneath:
Opexa Therapeutics Inc (NASDAQ:OPXA)’s shares dwindled -3.29%, and closed at $0.880.
Formerly on February 25, Opexa Therapeutics, Inc. (OPXA), a corporation developing personalized immunotherapies for autoimmune disorders, counting multiple sclerosis (MS) and neuromyelitis optica (NMO), declared that it has set 5:00 p.m. Eastern Time on March 13, 2015 as the record date for its forthcoming rights offering. Opexa intends to issue subscription rights to purchase units, composed of a share of Opexa ordinary stock and a warrant to purchase an additional share of ordinary stock, to holders of Opexa’s ordinary stock and Series L warrants on the record date. The subscription rights will expire if they are not exercised by 5:00 p.m. Eastern Time on April 8, 2015. Opexa may, in its sole discretion, extend the rights offering for additional periods and may cancel the rights offering at any time or for any reason preceding to the expiration date. Once made, all exercises of subscription rights are irrevocable.
Under the rights offering, Opexa will distribute one non-transferable subscription right for each share of ordinary stock held on the record date. Opexa’s ordinary stock will trade ex-rights on March 11, 2015. Each right will entitle the holder to purchase one unit, composed of one share of ordinary stock and a warrant to purchase ordinary stock at the subscription price of $0.70 per unit. The three-year warrant will entitle the holder to purchase one share of ordinary stock at an exercise price of (i) $0.50 per share from the date of issuance through June 30, 2016, and (ii) $1.50 per share from July 1, 2016 through the warrant expiration date. Opexa has applied to list the warrants on NASDAQ, although there is no assurance that a sufficient number of subscription rights will be exercised so that the warrants will meet the minimum listing criteria to be accepted for listing on NASDAQ. The warrants will be redeemable if Opexa’s ordinary stock closes above $2.50 per share for 10 successive trading days.
Opexa Therapeutics, Inc. (OPXA), is a biopharmaceutical corporation developing a personalized immunotherapy with the potential to treat major illnesses, counting multiple sclerosis (MS) in addition to other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology.
Centurylink Inc (NYSE:CTL), declined -2.40%, and closed at $36.25.
Formerly on February 23, CenturyLink, Inc. (CTL), declared that its Board of Directors voted to declare a regular quarterly cash dividend of $0.54 per share, a portion of which will be payable out of capital surplus, on March 20, 2015, to shareholders of record on March 6, 2015.
CenturyLink is the third largest telecommunications corporation in the United States and is recognized as a leader in the network services market by technology industry analyst firms. The corporation is a global leader in cloud infrastructure and hosted IT solutions for enterprise customers.
CollabRx Inc (NASDAQ:CLRX), dipped -3.79%, and closed at $1.27.
CollabRx, Inc. (CLRX), declared that on March 2, 2015, the Corporation received the formal determination of the NASDAQ Listing Qualifications Panel indicating that the Corporation has satisfied all requirements for continued listing on The NASDAQ Capital Market, counting the minimum $2.5 million stockholders’ equity requirement. Accordingly, the hearing matter has been closed.
On March 3, CollabRx, Inc. declared the closing of its formerly declared underwritten public offering of 2,362,205 shares of its ordinary stock at an offering price of $1.27 per ordinary share. In addition, the underwriter exercised the over-allotment option to purchase an additional 354,330 shares. Gross proceeds to CollabRx from this offering are about $3,450,000 before deducting underwriting discounts and commissions and other estimated offering expenses payable by CollabRx.
Aegis Capital Corp. acted as the sole book-running manager for the offering.
CollabRx, Inc. (CLRX) is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.
Cheniere Energy, Inc (NYSEMKT:LNG), dropped -3.65%, and closed at $78.43.
Cheniere Energy, Inc. (LNG): The president of the Swiss/Norwegian International Gas Union told reporters last week that destination clauses on contracts for liquefied natural gas (LNG) shipments “will soon be a thing of the past because of the shale revolution in the United States,” according to Reuters.
New LNG Market Dynamic:
The shale boom flipped the U.S. LNG market upside down in just over a decade — converting the U.S. from an importer of LNG into a soon-to-be exporter.
To accomplish this, billions of dollars of capital have been raised and new companies have been built to take the natural gas from U.S. producers and supercool it into liquid form for shipping abroad. A number of U.S. LNG export plants are in the design phase, and some plants are well under construction.
First movers have presold their planned output capacity in large part to Asian and European buyers. In fact, LNG plant developers in the U.S. have declared plans to export 50 million tonnes a year from projects going up along the Gulf Coast by 2018.
Cheniere Energy, Inc., an energy corporation, engages in the liquefied natural gas (LNG) related business. It operates through two segments, LNG Terminal Business, and LNG and Natural Gas Marketing Business.
